Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07377396 | A Study to Assess the Safety of ARGX-124 in Healthy Volunteers | PHASE1 | RECRUITING | 104 | — | — | Jan 26, 2026 | Dec 31, 2026 | Mar 6, 2026 | 1 | Canada |
AE : adverse event ; SAE : serious adverse event.
| Arm | Type | Description |
|---|---|---|
| ARGX-124 | EXPERIMENTAL | Participants receiving the experimental drug |
| Placebo | PLACEBO_COMPARATOR | Participants receiving placebo |
| Name | Type | Description |
|---|---|---|
| ARGX-124 | BIOLOGICAL | Administrations of ARGX-124 |
| Placebo | OTHER | Administrations of placebo comparator |
Inclusion Criteria: * Is at least the local legal age of consent and aged 18 to 65 years, inclusive, when signing the ICF. * Is a female of Nonchildbearing Potential (postmenopausal or surgically sterilized) or a male. * Has a body weight between 50 and 120 kg and a BMI between 18 and 30.5 kg/m2, i...